Neutral impactResults

Dr Reddy’s Q2 Results: Net profit falls as lower Lenalidomide sales hit revenue; beats estimates

CNBC-TV18 1 hr ago·23 Oct 2026, 1:06 pm

Dr Reddy’s Laboratories reported a 36% YoY decline in Q2 FY27 net profit to ₹913.4 crore, while revenue fell 1.5% to ₹8,671 crore. The company beat CNBC-TV18 poll estimates for net profit, revenue, EBITDA and EBITDA margin, despite year-on-year declines in profitability and operating margin.

Affected stocks

Neutral1 stock

Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.

Key takeaways

  • Concerns DR. Reddy S Laboratories (DRREDDY).
  • Category: Results.

Why it matters

A routine update for DR. Reddy S Laboratories. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at CNBC-TV18.

More Stocks news

More news

Latest headlines

More news

Aggregated from third-party sources for research. Sentiment & impact are AI-generated, indicative, not advice.